Background: Mental health problems increased during the COVID-19 pandemic. Knowledge that one is less at risk after being vaccinated may alleviate distress, but this hypothesis remains unexplored. Here we test whether psychological distress declined in those vaccinated against COVID-19 in the US and whether changes in perceived risk mediated any association. Methods: A nationally-representative cohort of U.S. adults (N=5,792) in the Understanding America Study were interviewed every two weeks from March 2020 to June 2021 (28 waves). Difference-in-difference regression tested whether getting vaccinated reduced distress (PHQ-4 scores), with mediation analysis used to identify potential mechanisms, including perceived risks of infection, hospitalization, and death. Results: Vaccination was associated with a 0.09 decline in distress scores (95% CI:-0.15 to -0.04) (0-12 scale), a 5.7% relative decrease compared to mean scores in the wave prior to vaccination. Vaccination was also associated with an 8.44 percentage point reduction in perceived risk of infection (95% CI:-9.15% to -7.73%), a 7.44-point reduction in perceived risk of hospitalization (95% CI:-8.07% to -6.82%), and a 5.03-point reduction in perceived risk of death (95% CI:-5.57% to -4.49%). Adjusting for risk perceptions decreased the vaccination-distress association by two-thirds. Event study models suggest vaccinated and never vaccinated respondents followed similar PHQ-4 trends pre-vaccination, diverging significantly post-vaccination. Analyses were robust to individual and wave fixed effects, time-varying controls, and several alternative modelling strategies. Results were similar across sociodemographic groups. Conclusion: Receiving a COVID-19 vaccination was associated with declines in distress and perceived risks of infection, hospitalization, and death. Vaccination campaigns could promote these additional benefits of being vaccinated.
Background Household transmission studies offer the opportunity to assess both secondary attack rate and persistence of SARS-CoV-2 antibodies over time. Methods We invited confirmed COVID-19 cases and their household members to attend up to four household visits with collection of nasopharyngeal and serum samples over 28 days after index case onset. We calculated secondary attack rates (SAR) based on the presence of SARS-CoV-2 nucleoprotein IgG antibodies (IgG Ab) and/or neutralizing antibodies (NAb) overall and per households. Three and six months later, we assessed the persistence of SARS-CoV-2 antibodies. Findings We recruited 39 index cases and 90 household members. Among 87 household members evaluated, SAR was 48% (n=42), including 37 symptomatic secondary cases. In total, 80/129 (62%) participants developed both IgG Ab and NAb, while three participants only developed IgG Ab. Among participants who had both IgG Ab and NAb during the initial follow-up, 68/69 (99%) and 63/70 (90%) had IgG Ab and NAb at 3 months, while at 6 months, 59/75 (79%) and 63/75 (84%) had IgG Ab and NAb, respectively. Participants who required hospital care had initially 5-fold IgG Ab concentrations compared to cases with mild symptoms and 8-fold compared to asymptomatic cases. Interpretation Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. Follow-up of participants showed strong persistence of antibodies in most cases. Funding This study was supported by THL coordinated funding for COVID-19 research (Finnish Government9s supplementary budget) and by the Academy of Finland (Decision number 336431).
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults - Conditions: COVID-19; SARS-CoV-2
Interventions: Biological: AZD1222; Biological: AZD2816
Sponsor: AstraZeneca
Recruiting
Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans’ Perceptions/Beliefs About COVID-19 Testing and Vaccination Study - Condition: Covid19 Virus Infection
Intervention: Behavioral: Protect Your Elders Campaign
Sponsors: North Carolina Central University; Lumbee Tribe of North Carolina; University of North Carolina at Pembroke
Recruiting
Effects of Respiratory Muscle Training in Patients With Post COVID-19 - Condition: Covid19
Interventions: Other: Exercise training group; Other: Control training group
Sponsor: Gazi University
Completed
SOLIDARITY Finland Long COVID-19 - Condition: Covid19
Intervention: Drug: Remdesivir
Sponsors:
Clinical Urology and Epidemiology Working Group; University of Helsinki; World Health Organization; Helsinki University Central Hospital; Hyvinkää Hospital; Kanta-Häme Central Hospital; Kuopio University Hospital; Oulu University Hospital; Porvoo Hospital; Seinajoki Central Hospital; Mikkeli Central Hospital; Tampere University Hospital
Recruiting
Vaccination for Recovered Inpatients With COVID-19 (VATICO) - Condition: Covid19
Interventions: Biological: Moderna mRNA-1273 COVID-19 vaccine; Biological: Pfizer BNT162b2 COVID-19 vaccine
Sponsors: International Network for Strategic Initiatives in Global HIV Trials (INSIGHT); University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID); University of Copenhagen; Kirby Institute; Washington D.C. Veterans Affairs Medical Center; AIDS Clinical Trials Group; National Heart, Lung, and Blood Institute (NHLBI); US Department of Veterans Affairs; Prevention and Early Treatment of Acute Lung Injury (PETAL); Cardiothoracic Surgical Trials Network (CTSN); Medical Research Council
Not yet recruiting
Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome - Condition: Long COVID-19
Intervention: Behavioral: Multidisciplinary Rehabilitation
Sponsors: Danderyd Hospital; St Göran Hospital, Stockholm
Recruiting
Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake - Conditions: Covid19; COVID-19 Vaccine
Interventions:
Behavioral: Tailored COVID-19 vaccine messages; Other: Other health messages
Sponsors:
Hopital Montfort; Public Health Agency of Canada (PHAC); Eastern Ontario Health Unit
Not yet recruiting
Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19 - Condition: COVID-19 Acute Respiratory Distress Syndrome
Intervention:
Drug: Potassium Canrenoate
Sponsors: Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico; University of Milan; IRCCS Azienda Ospedaliero-Universitaria di Bologna
Not yet recruiting
COVID-19 and Lung Ultrasound Utility - Condition: Covid19
Intervention: Device: Device: Butterfly iQ
Sponsor:
Rocket Doctor Inc.
Recruiting
Saliva-based COVID-19 DNA Aptamer Test - Condition: Covid19
Intervention: Device: AptameX
Sponsors: Achiko AG; Udayana University
Recruiting
Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus - Condition: COVID-19 Pneumonia
Interventions: Drug: Baricitinib; Drug: Dexamethasone; Drug: Remdesivir
Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Recruiting
Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19 - Condition: COVID19
Interventions: Device: RD-X19; Device: Sham
Sponsor:
EmitBio Inc.
Recruiting
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19 - Condition: Covid19
Intervention: Drug: standard treatment COVID-19 + Triazavirin
Sponsor: Ain Shams University
Recruiting
Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19 - Condition: Covid19
Intervention: Drug: Hydroxychloroquine with Azithromycin
Sponsors: Coordinación de Investigación en Salud, Mexico; Ultra Laboratorios SA. de CV.
Recruiting
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes - Condition: COVID-19 Vaccines
Intervention: Drug: Gam-COVID-Vac / Gam-COVID-Vac
Sponsor: Ministerio de Salud de Ciudad Autónoma de Buenos Aires
Recruiting
Author Correction: Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication - No abstract
SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block - The transcriptional induction of interferon (IFN) genes is a key feature of the mammalian antiviral response that limits viral replication and dissemination. A hallmark of severe COVID-19 disease caused by SARS-CoV-2 is the low presence of IFN proteins in patient serum despite elevated levels of IFN-encoding mRNAs, indicative of post-transcriptional inhibition of IFN protein production. Here, we performed single-molecule RNA visualization to examine the expression and localization of host mRNAs…
Remdesivir analogs against SARS-CoV-2 RNA-dependent RNA polymerase - The COVID-19 pandemic has already taken many lives but is still continuing its spread and exerting jeopardizing effects. This study is aimed to find the most potent ligands from 703 analogs of remdesivir against RNA-dependent RNA polymerase (RdRp) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus . RdRp is a major part of a multi- subunit transcription complex of the virus, which is essential for viral replication. In clinical trials, it has been found that remdesivir…
Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets - A subset of patients with COVID-19 become critically ill, suffering from severe respiratory problems and also increased rates of thrombosis. The causes of thrombosis in severely ill COVID-19 patients are still emerging, but the coincidence of critical illness with the timing of the onset of adaptive immunity could implicate an excessive immune response. We hypothesised that platelets might be susceptible to activation by anti-SARS-CoV-2 antibodies and contribute to thrombosis. We found that…
Network pharmacology and molecular docking analysis on mechanisms of Tibetan Hongjingtian (Rhodiola crenulata) in the treatment of COVID-19 - Introduction. Coronavirus disease 2019 (COVID-19) is a highly contagious disease and ravages the world.Hypothesis/Gap Statement. We proposed that R. crenulata might have potential value in the treatment of COVID-19 patients by regulating the immune response and inhibiting cytokine storm.Aim. We aimed to explore the potential molecular mechanism for Rhodiola crenulata (R. crenulata), against the immune regulation of COVID-19, and to provide a referenced candidate Tibetan herb (R. crenulata) to…
Application of nano-graphene oxide as nontoxic disinfectant against alpha and betacoronaviruses - New viruses are continuously emerging and recently there have been many great concerns on severe acute respiratory syndrome coronavirus (SARS-CoV-2). Nanographene oxide (nanoGO) has received much attention and is widely investigated to be utilised in therapy for infectious diseases by viruses. Thus, antiviral activity of nanoGO was evaluated using the porcine epidemic diarrhoea virus (PEDV), bovine coronavirus (BCoV), and SARS-CoV-2, which are all Alpha- and Beta- coronavirus. In a virus…
Natural Products with tandem Anti-inflammatory, Immunomodulatory and Anti-SARS-CoV/2 effects: A Drug Discovery Perspective against SARS-CoV-2 - CONCLUSION: This study revealed that amentoflavone, rubranoside B, savinin, psoralidin, hirsutenone, and papyriflavonol A are good drug candidate for the search of antibiotics against COVID-19.
Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study - The scientific community is working against the clock to arrive at therapeutic interventions to treat patients with COVID-19. Among the strategies for drug discovery, virtual screening approaches have the capacity to search potential hits within millions of chemical structures in days, with the appropriate computing infrastructure. In this article, we first analyzed the published research targeting the inhibition of the main protease (Mpro), one of the most studied targets of SARS-CoV-2, by…
Integrin activation is an essential component of SARS-CoV-2 infection - Cellular entry of coronaviruses depends on binding of the viral spike (S) protein to a specific cellular receptor, the angiotensin-converting enzyme 2 (ACE2). Furthermore, the viral spike protein expresses an RGD motif, suggesting that cell surface integrins may be attachment co-receptors. However, using infectious SARS-CoV-2 requires a biosafety level 3 laboratory (BSL-3), which limits the techniques that can be used to study the mechanism of cell entry. Here, we UV- inactivated SARS-CoV-2 and…
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics - SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase and the exonuclease could overcome this deficiency. Here we report the identification of hepatitis C virus NS5A inhibitors Pibrentasvir and Ombitasvir as SARS- CoV-2 exonuclease inhibitors. In the…
In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19 - SARS-CoV-2 has caused millions of infections and hundreds of thousands of deaths globally. Presently, no cure for SARS- CoV-2 infection is available; thus, all hands are on deck for new drug discovery. Although, several studies have reported the potentials of some already approved drugs for the treatment of COVID-19. This study attempted to compare the potency and safety of some these trial drugs via in silico methods. The binding affinity and interactions of the trial drugs with proteins…
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach - The RNA-dependent RNA polymerase (RdRp) and 3C-like protease (3CLpro) from SARS-CoV-2 play crucial roles in the viral life cycle and are considered the most promising targets for drug discovery against SARS-CoV-2. In this study, FDA- approved drugs were screened to identify the probable anti-RdRp and 3CLpro inhibitors by molecular docking approach. The number of ligands selected from the PubChem database of NCBI for screening was 1760. Ligands were energy minimized using Open Babel. The RdRp and…
Transcription factor NF-kappaB as target for SARS-CoV-2 drug discovery efforts using inflammation-based QSAR screening model - NF-κB is a central regulator of immunity and inflammation. It is suggested that the inflammatory response mediated by SARS-CoV-2 is predominated by NF-κB activation. Thus, NF-κB inhibition is considered a potential therapeutic strategy for COVID-19. The aim of this study was to identify potential anti-inflammation lead molecules that target NF-κB using a quantitative structure-activity relationships (QSAR) model of currently used and investigated anti-inflammatory drugs as the basis for…
Computational modeling predicts potential effects of the herbal infusion “horchata” against COVID-19 - Bioactive plant-derived molecules have emerged as therapeutic alternatives in the fight against the COVID-19 pandemic. In this investigation, principal bioactive compounds of the herbal infusion “horchata” from Ecuador were studied as potential novel inhibitors of the SARS-CoV-2 virus. The chemical composition of horchata was determined through a HPLC- DAD/ESI-MS^(n) and GC-MS analysis while the inhibitory potential of the compounds on SARS-CoV-2 was determined by a computational prediction using…
The potential role of thymoquinone in preventing the cardiovascular complications of COVID-19 - A new virus strain detected in late 2019 and not previously described in humans is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes corona virus disease (COVID-19). While potential therapeutic approaches for COVID-19 are being investigated, significant initiatives are being made to create protective drugs and study various antiviral agents to cure the infection. However, an effective treatment strategy against COVID-19 is worrisome inadequate. The objective of the…
A SYSTEM AND METHOD FOR COVID- 19 DIAGNOSIS USING DETECTION RESULTS FROM CHEST X- RAY IMAGES - - link
Advanced Machine Learning System combating COVID-19 virus Detection, Spread, Prevention and Medical Assistance. - - link
一种包装重组流感病毒的重组载体和重组流感病毒及其构建方法和应用 - 本发明提供了一种包装重组流感病毒的重组载体和重组流感病毒及其构建方法和应用,涉及生物医药技术领域。本发明利用A型流感病毒八个基因片段为骨架包装出带有新型冠状病毒SARS‑CoV‑2表面刺突蛋白受体结合域(SARS‑CoV‑2_RBD)片段的重组流感病毒,此重组流感病毒可在复制过程中表达具有生物学活性和免疫原性的刺突蛋白受体结合区域RBD。本发明所述重组流感病毒rgH1N1(PR8)‑PA‑RBD可作为重组病毒类药物,用于2019新型冠状病毒肺炎(COVID‑19)的预防;也可作为体外SARS‑COV‑2 RBD等相关抗原表达和体内递呈系统。 - link
Differential detection kit for common SARS-CoV-2 variants in COVID-19 patients - - link
一种新型冠状病毒的mRNA疫苗 - 本发明公开了一种新型冠状病毒的mRNA疫苗。本发明提供的疫苗,其活性成分为mRNA,如序列表的序列6所示。本发明还保护TF‑RBD蛋白,如序列表的序列2所示。本发明的发明人通过一系列序列设计和序列优化得到了特异DNA分子,进一步构建了特异重组质粒,将特异重组质粒进行体外转录,可以得到多聚化TF‑RBD mRNA。进一步的,发明人制备了负载TF‑RBD mRNA的脂质纳米粒。本发明对于新型冠状病毒的防控具有重大的应用推广价值。 - link
新型冠状病毒B.1.1.7英国突变株RBD的基因及其应用 - 本发明属于生物技术领域,具体涉及新型冠状病毒B.1.1.7英国突变株RBD的基因及其应用。本发明的新型冠状病毒B.1.1.7英国突变株RBD的基因,其核苷酸序列如SEQ ID NO.1或SEQ ID NO.6所示。本发明通过优化野生型新型冠状病毒B.1.1.7英国突变株RBD的基因序列,并结合筛选确定了相对最佳序列,优化后序列产生的克隆表达效率比野生型新型冠状病毒B.1.1.7英国突变株RBD序列表达效率大幅提高,从而,本发明的新型冠状病毒B.1.1.7英国突变株RBD的基因更有利于用于制备新型冠状病毒疫苗。 - link
SARS-CoV-2 anti-viral therapeutic - - link
一种基于联邦学习的多用户协同训练人流统计方法及系统 - 本发明提供一种基于联邦学习的多用户协同训练人流统计方法,旨在利用联邦学习框架搭建一个新颖的人群计数模型,达到让多用户多设备同时训练的目的。各个客户端利用图像数据集对图像分类网络进行本地训练以获取本地模型;在各经过至少一次本地训练后,中心服务器从客户端获取本地模型的权值及附加层参数并进行聚合处理;中心服务器利用聚合处理后的权值及附加层参数更新全局模型,并将聚合处理后的权值参数及附加层参数返回给各个客户端;各个客户端利用中心服务器返回的权值以及ground truth值进行贝叶斯估计,计算loss值,并利用返回的权值参数及附加层参数更新本地模型;重复执行直至所有客户端的loss值均收敛,则完成人流统计全局模型和本地模型的训练。 - link
A POLYHERBAL ALCOHOL FREE FORMULATION FOR ORAL CAVITY - The present invention generally relates to a herbal composition. Specifically, the present invention relates to a polyherbal alcohol free composition comprising of Glycyrrhiza glabra root extract, Ocimum sanctum leaf extract, Elettaria cardamomum fruit extract, Mentha spicata (Spearmint) oil and Tween 80 and method of preparation thereof. The polyherbal alcohol free composition of the present invention possesses excellent antimicrobial properties and useful for oral cavity. - link
新型冠状病毒B.1.351南非突变株RBD的基因及其应用 - 本发明属于生物技术领域,具体涉及新型冠状病毒B.1.351南非突变株RBD的基因及其应用。本发明的新型冠状病毒B.1.351南非突变株RBD的基因,其核苷酸序列如SEQIDNO.1或SEQIDNO.6所示。本发明通过优化野生型新型冠状病毒南非B.1.351南非突变株RBD的基因序列,并结合筛选确定了相对最佳序列,优化后序列产生的克隆表达效率比野生型新型冠状病毒B.1.351南非突变株RBD序列表达效率大幅提高,从而,本发明的新型冠状病毒B.1.351南非突变株RBD的基因可以用于制备新型冠状病毒疫苗。 - link